Login / Signup

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial.

Kaitlin J MayneRebecca J SardellNatalie StaplinParminder K JudgeDoreen ZhuEmily SammonsDavid Zi CherneyAlfred K CheungAldo Pietro MaggioniMasaomi NangakuXavier RosselloKatherine R TuttleKatsuhito IharaTomoko IwataChristoph WannerJonathan R EmbersonDavid PreissMartin J LandrayColin Baigent FMedSciRichard HaynesWilliam G Herringtonnull null
Published in: Clinical journal of the American Society of Nephrology : CJASN (2024)
These findings support the use of SGLT2 inhibitors in CKD, irrespective of frailty, multimorbidity or polypharmacy.
Keyphrases
  • community dwelling
  • chronic kidney disease
  • adverse drug
  • study protocol
  • phase iii
  • clinical trial
  • phase ii
  • emergency department
  • double blind
  • drug induced